1

2
Chen Yuanwei, O Connor Stephen James, Gunn David, Newcom Jason, Chen Jianqing, Yi Lin, Zhang Hai Jun, Hunyadi Laszlo Matyas, Natero Reina: Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity. Bayer Pharmaceuticals Corporation, Chen Yuanwei, O Connor Stephen James, Gunn David, Newcom Jason, Chen Jianqing, Yi Lin, Zhang Hai Jun, Hunyadi Laszlo Matyas, Natero Reina, GREENMAN Jeffrey M, July 15, 2004: WO/2004/058727 (45 worldwide citation)

This invention relates to substituted 3,5-dihydro-4H-imidazol-4-ones compounds which are useful in the treatment of obesity and obesity-related disorders, and as weight-loss and weight-control agents. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions com ...


3
Wood Jill E, Chen Yuanwei, Hart Barry, Yi Lin, Chen Jianqing: Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders. Bayer Pharmaceuticals Corporation, Wood Jill E, Chen Yuanwei, Hart Barry, Yi Lin, Chen Jianqing, GREENMAN Jeffrey M, May 13, 2004: WO/2004/039359 (43 worldwide citation)

A method of treating hyper-proliferative disorders comprising the administration to a patient in need thereof of an effective amount of a compound of Formula (I) wherein R is halo or CF3; n is 0 or 1; R1 is selected independently in each instance from the group consisting of halo, (C1-C3)alkoxy, and ...


4

5
Clairmont Kevin, Lumb Kevin, Whelan James: (gip) Receptor agonists and their pharmacological methods of use. Bayer Pharmaceuticals Corporation, Clairmont Kevin, Lumb Kevin, Whelan James, GREENMAN Jeffrey M, November 16, 2006: WO/2006/121904 (33 worldwide citation)

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the GIP receptor. The peptides of the present invention provide a new therapy for pa ...


6

7

8

9
Sweet Laurel: Methods for treating diabetes and related disorders using pde10a inhibitors. Bayer Pharmaceuticals Corporation, Sweet Laurel, GREENMAN Jeffrey M, February 10, 2005: WO/2005/012485 (20 worldwide citation)

The methods of the invention relate to the treatment of diabetes, including type 2 diabetes, and related disorders by administration of a PDE10A inhibitor. Such PDE10A inhibitors may be administered in conjunction with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic ...


10